Find the right fit for you - faster
Get tailored insights about working at Accelerate Brain Cancer Cure in one quick step.
Accelerate Brain Cancer Cure Snapshot
ABC2's mission is to accelerate a cure for brain cancer by increasing the number of potential therapies and moving them rapidly into the clinic for patients. We look forward to the day when all patients who are diagnosed with brain cancer are told they have a manageable disease.
We believe that a nimble, focused and aggressive entrepreneurial model will increase the number of therapies discovered and then enable those therapies to be more rapidly driven into the clinic.
We provide researchers with the pivotal support they need to make critical breakthroughs. We fund novel translational research aimed at finding the fastest possible route to a cure for brain cancer.
Our partners range from medical research centers to early-stage biotechnology companies to large multi-national pharmaceutical companies. These partners all share a vision of driving translational research and moving treatments as fast as possible from basic discovery to the clinic.
Since brain cancer affects a relatively small portion of the population, we recognize the importance of investing in the early stages of the most novel sectors of the discovery and development pipeline in order to “buy down the risk” for our partners and speed progress of innovative new treatments to the clinic.
We provide researchers with the pivotal support they need to make critical breakthroughs. We fund novel translational research aimed at finding the fastest possible route to a cure for brain cancer.
Our partners range from medical research centers to early-stage biotechnology companies to large multi-national pharmaceutical companies. These partners all share a vision of driving translational research and moving treatments as fast as possible from basic discovery to the clinic.
Since brain cancer affects a relatively small portion of the population, we recognize the importance of investing in the early stages of the most novel sectors of the discovery and development pipeline in order to “buy down the risk” for our partners and speed progress of innovative new treatments to the clinic.
